Loading
A phase 2 trial of BAY2927088 in advanced solid tumours, run by Bayer, now recruiting.
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) is a phase 2 interventional study registered as NCT06760819 by Bayer, with 111 participants planned, started 2025-02-13 and due to reach its primary completion in 2029-02-02. Interventions recorded: BAY2927088.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bayer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bayer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bayer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bayer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/